GIL KLIMAN

Gil Kliman stands as a highly respected Managing Partner at InterWest Partners, a prominent venture capital firm with a long history of backing groundbreaking companies. At InterWest, Gil plays a pivotal role in identifying and nurturing innovative startups, primarily focusing on the dynamic healthcare sector. His investment strategy centers on transformative opportunities within medical devices, diagnostics, and the rapidly evolving field of digital health, leveraging his unique blend of medical expertise and entrepreneurial acumen.

Gil's journey into venture capital is distinguished by a deep understanding of both clinical needs and business strategy. A physician by training, he earned his MD from the University of California, San Francisco, and an MBA from Stanford University, following his undergraduate studies at Harvard. This robust educational foundation provided him with a comprehensive perspective on healthcare innovation. Before joining InterWest Partners in 1996, Gil co-founded and served as CEO of Advanced Cardiovascular Systems (ACS), a pioneering medical device company that was later acquired by Eli Lilly and subsequently by Johnson & Johnson. This hands-on experience as an entrepreneur gives him invaluable insight into the challenges and triumphs faced by founders. Prior to InterWest, he also honed his venture capital skills as a General Partner at Mayfield Fund.

Throughout his tenure at InterWest, Gil Kliman has been instrumental in the growth and success of numerous portfolio companies, often serving on their boards of directors. His strategic guidance and deep industry connections have helped many ventures navigate complex regulatory landscapes and achieve significant market penetration. Notable investments reflecting his keen eye for innovation include Glaukos (a leader in glaucoma treatment), Inspire Medical Systems (pioneering solutions for sleep apnea), and NeoTract (developer of a minimally invasive treatment for BPH). In the digital health space, he backed Livongo Health, which went public and was later acquired by Teladoc, demonstrating his foresight in emerging healthcare technologies. Other successful exits include LenSx Lasers (acquired by Alcon/Novartis) and Ulthera (acquired by Merz).

Gil Kliman's commitment to advancing healthcare through strategic investment continues to make a significant impact. His ability to identify disruptive technologies and support visionary entrepreneurs solidifies his reputation as a leading figure in the venture capital community, dedicated to fostering companies that improve patient outcomes and reshape the future of medicine.